RenovoRx

Yahoo Finance • 3 days ago

Biotech Stocks Shine After Hours: Novo Nordisk, IDEAYA, Healthcare Triangle Among Gainers

(RTTNews) - Healthcare and biotechnology stocks saw notable moves in after-hours trading on Monday, with several companies posting strong gains despite limited news flow. Novo Nordisk A/S (NVO) surged in extended trading, climbing 9.48% t... Full story

Yahoo Finance • 14 days ago

RenovoRx Announces Acceptance of Clinical Data Abstract at the ASCO Gastrointestinal Cancers Symposium 2026

MOUNTAIN VIEW, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented,... Full story

Yahoo Finance • 24 days ago

RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9th

MOUNTAIN VIEW, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (Nasdaq: RNXT) (“RenovoRx” or “the Company”), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA... Full story

Yahoo Finance • last month

RenovoRx CEO Shaun Bagai to Present at the Alliance Global Partners Emerging AgBiotech/Bio-Solutions Virtual Showcase on November 20th

MOUNTAIN VIEW, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (Nasdaq: RNXT) (“RenovoRx” or “the Company”), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA... Full story

Yahoo Finance • last month

RenovoRx GAAP EPS of -$0.08 in-line, revenue of $0.2M misses by $0.1M

* RenovoRx press release [https://seekingalpha.com/pr/20307315-renovorx-reports-third-quarter-2025-financial-results-including-approximately-900000-in-year] (RNXT [https://seekingalpha.com/symbol/RNXT]): Q3 GAAP EPS of -$0.08 in-line.... Full story

Yahoo Finance • last month

RenovoRx Reports Third Quarter 2025 Financial Results, Including Approximately $900,000 in Year-to-Date Revenue, and Provides Business Update

September 30, 2025 Cash and Cash Equivalents at $10 million Revenue Expected to Grow in 2026 and Continue to Offset Cash Burn Management to Host Conference Call Today at 4:30 p.m. ET MOUNTAIN VIEW, Calif., Nov. 13, 2025 (GLOBE NEWSWIR... Full story

Yahoo Finance • 2 months ago

Exploring 3 High Growth Tech Stocks in US Market

As the U.S. market grapples with a mix of earnings reports and renewed U.S.-China trade tensions, major stock indexes have been under pressure, with the tech-heavy Nasdaq and other indices closing lower. In this environment, identifying hi... Full story

Yahoo Finance • 3 months ago

RenovoRx’s PanTheR Post-Marketing Registry Study Progresses with First Clinical Procedure and Addition of Two Participating Clinical Sites

First Registry-Eligible Patient Procedure Commenced at the University of Vermont Cancer Center Baptist Health Miami Cancer Institute and University of Pittsburgh Medical Center Join the University of Vermont Cancer Center as Participating... Full story

Yahoo Finance • 3 months ago

RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Fall Investment Conference 2025 on September 16th

MOUNTAIN VIEW, Calif., Sept. 11, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented,... Full story

Yahoo Finance • 4 months ago

Curious about the stocks that are showing activity after the closing bell on Wednesday?

As the regular session of the US market on Wednesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment. [postmarket] GAINERS TICKER CHANGE COMMENT... Full story

Yahoo Finance • 5 months ago

RenovoRx expands commercial footprint to 13 cancer centers

MOUNTAIN VIEW, Calif. - RenovoRx, Inc. (NASDAQ:RNXT), a medical device company with a market capitalization of $44.6 million and strong balance sheet showing more cash than debt, has expanded its commercial footprint to 13 cancer centers a... Full story

Yahoo Finance • 5 months ago

RenovoRx Expands U.S. Commercialization Efforts for the RenovoCath® Device with Growing Customer Demand and Key Leadership Hire

RenovoRx increases its commercial footprint to thirteen leading National Cancer Institute-designated and community centers approved to purchase RenovoCath Four active cancer center customers are currently purchasing and have made repeat o... Full story

Yahoo Finance • 6 months ago

Kemira Q1 2025 presentation: Solid profitability maintained amid softer market

Introduction & Market Context Finnish chemicals company Kemira reported its first quarter 2025 results on April 25, demonstrating resilience in a challenging market environment. Despite facing increased market uncertainty and softer deman... Full story

Yahoo Finance • 6 months ago

RenovoRx shareholders elect directors and approve incentive plan amendments

RenovoRx , Inc. (NASDAQ:RNXT) announced the results of its 2025 annual meeting of stockholders held Tuesday. According to a press release statement based on the company’s SEC filing, shareholders voted on three proposals. First, all nomin... Full story